Sectors:
Min Investment:
Max Investment:
Target Investment:
2018
2018
At Erasca, our mission is in our name: to erase cancer. Co-Founded company in July 2018, joined as Executive Chairman in October 2018, and transitioned to Chairman and CEO in March 2019.
2018
ARCH Venture Partners, one of the largest early stage technology venture firms in the U.S., founds and invests in disruptive biotechnology companies. ARCH has co-founded or seeded companies that have pioneered gene sequencing, genomics, immunotherapy, gene therapy, cell therapy, vaccines, infectious disease treatments, and early disease detection. Over three decades, ARCH has raised approximately $9 billion of committed capital through 12 venture funds, and has invested in the early rounds of more than 25 companies that have reached $1 billion market capitalization. www.archventure.com.
2019
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics. Advances in these areas have enabled us to decode the mysteries of genetic modifiers in a range of severe diseases, which we aim to turn into medicines that mimic protective mutations. We have assembled a world-class team that we need to realize this vision, including creative scientific pioneers in genetics, experienced company builders and biotech industry leaders.
2018
2018
Co-Founded Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, in December 2018. Boundless Bio is leveraging new discoveries about the role of ecDNA in driving cancer growth, resistance and recurrence to develop the first ecDNA-targeting medicines and transform outcomes for patients with high copy number, focal gene amplification-driven cancers, which historically have been very difficult to treat.
2010
2010
Founded City Hill, an impact-minded investment firm dedicated to revitalizing people, planet and perspective, in December 2010. City Hill founds, funds and leads mission-driven for-profit and non-profit ventures through its family of entities, City Hill Ventures (launched in 2010), City Hill Foundation (launched in 2011) and City Hill Arts (launched in 2018).
2015 - 2018
2015 - 2018
Co-Founded Bonti, a biotech company developing next-generation neurotoxins for unmet needs in post-surgical pain management/ analgesia and aesthetic medicine, in August 2015; joined company as Chairman in February 2016. The company was acquired by Allergan plc (NYSE: AGN) for an upfront payment of US$195M and additional potential commercial milestone payments in October 2018.
2011 - 2018
2011 - 2018
Co-Founded Ignyta, a precision medicine biotech company aspiring to eradicate residual disease in precisely defined populations of patients with cancer, in August 2011. Led the in-licensing and global development of its lead cancer therapy, ROZLYTREK® (entrectinib), now approved by US FDA and PMDA for ROS1-positive non-small cell lung cancer and NTRK gene fusion-positive solid tumors. Led Ignyta’s trailblazing pursuit of a global tissue agnostic label to transform cancer treatment with ROZLYTREK® that became the first drug in biopharmaceutical history to achieve the unprecedented triple crown of breakthrough designations with BTD (FDA), PRIME (EMA) and Sakigake (PMDA). Helped take company public in October 2013 (NASDAQ: RXDX). Led the company through its acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) in February 2018 for a total transaction value of US$1.7 billion, and its subsequent integration into Roche and Genentech in July 2018. Ignyta is now a key personalized healthcare pillar of the leading precision oncology company in the world, as a wholly-owned subsidiary of Roche Holdings, Inc. (RHI), and an affiliate of Genentech, Inc., a wholly-owned subsidiary of RHI.
2011 - 2012
2011 - 2012
Co-Founded Eclipse Therapeutics, a Biogen Idec spinout company developing monoclonal antibody therapeutics targeting cancer stem cells, in March 2011. Eclipse was successfully acquired just 18 months from inception in 2012 by Bionomics Ltd. (ASX: BNO).
2003 - 2010
2003 - 2010
Led Halozyme, a biotech company with recombinant human PH20 (rHuPH20) hyaluronidase platform technology. Designed and executed landmark deals for Halozyme's ENHANZE® drug delivery technology with Roche/Genentech and Baxter that formed the foundational business model and template for the company’s ten global alliances and five approved ENHANZE products that have enabled Halozyme to turn EBITDA positive and guide to $1 billion in royalty revenue in 2027. Helped lead the development of rHuPH20 technology that resulted in global regulatory approval and launch of: (1) HYLENEX® recombinant (U.S. in 2005); (2) Herceptin® Hylecta/SC (EU in 2013; U.S. in 2019); (3) HYQVIA® (U.S. in 2014; EU, Puerto Rico, Australia); (4) MabThera® SC (EU in 2016; OUS); RITUXAN HYCELA™ (U.S. in 2017); (5) DARZALEX FASPRO™ (U.S. and EU in 2020); and (6) Phesgo™ (Perjeta® and Herceptin® SC; U.S. in 2020). Helped take Halozyme public in 2004 (NASDAQ: HALO), raised ~$300 million from 2003 to 2010, and the company has subsequently reached a multi-billion dollar peak market cap.
2001 - 2003
2001 - 2003
Active member of McKinsey's West Coast Health Care Practice, serving a wide range of start-ups to Fortune 500 companies in the biopharmaceutical, medical products, and payer/provider segments.